DK0920429T3 - Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater - Google Patents

Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater

Info

Publication number
DK0920429T3
DK0920429T3 DK97929472T DK97929472T DK0920429T3 DK 0920429 T3 DK0920429 T3 DK 0920429T3 DK 97929472 T DK97929472 T DK 97929472T DK 97929472 T DK97929472 T DK 97929472T DK 0920429 T3 DK0920429 T3 DK 0920429T3
Authority
DK
Denmark
Prior art keywords
pyrimido
substituted pyrido
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
DK97929472T
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0920429T3 publication Critical patent/DK0920429T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97929472T 1996-08-06 1997-07-23 Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater DK0920429T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06
PCT/IB1997/000918 WO1998005661A1 (en) 1996-08-06 1997-07-23 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Publications (1)

Publication Number Publication Date
DK0920429T3 true DK0920429T3 (da) 2003-05-12

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97929472T DK0920429T3 (da) 1996-08-06 1997-07-23 Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater

Country Status (40)

Country Link
US (1) US6492520B1 (da)
EP (1) EP0920429B1 (da)
JP (1) JP3345021B2 (da)
KR (1) KR20000029843A (da)
CN (1) CN1093130C (da)
AP (1) AP1096A (da)
AR (1) AR008829A1 (da)
AT (1) ATE232863T1 (da)
AU (1) AU709203B2 (da)
BG (1) BG103143A (da)
BR (1) BR9710808A (da)
CA (1) CA2262692C (da)
CO (1) CO4900060A1 (da)
CZ (1) CZ292806B6 (da)
DE (1) DE69719193T2 (da)
DK (1) DK0920429T3 (da)
DZ (1) DZ2289A1 (da)
EA (1) EA003188B1 (da)
ES (1) ES2191183T3 (da)
GT (1) GT199700089A (da)
HR (1) HRP970432B1 (da)
ID (1) ID17980A (da)
IL (1) IL128188A0 (da)
IS (1) IS4948A (da)
MA (1) MA24296A1 (da)
NO (1) NO313293B1 (da)
NZ (1) NZ333727A (da)
OA (1) OA10970A (da)
PA (1) PA8435201A1 (da)
PE (1) PE97098A1 (da)
PL (1) PL331602A1 (da)
SA (1) SA97180334A (da)
SK (1) SK14099A3 (da)
TN (1) TNSN97135A1 (da)
TR (1) TR199900228T2 (da)
TW (1) TW550265B (da)
UY (1) UY24655A1 (da)
WO (1) WO1998005661A1 (da)
YU (1) YU5399A (da)
ZA (1) ZA976954B (da)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
DK1129096T3 (da) 1998-11-12 2003-09-15 Neurocrine Biosciences Inc CRF-receptorantagonister og fremgangsmåder, der er relateret dertil
ES2180338T3 (es) 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
RU2004112787A (ru) 2001-09-26 2005-10-10 Байер Фармасьютикалс Корпорейшн (US) Производные 1,6-нафтиридина как противодиабетические средства
MXPA04010267A (es) * 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA013248B1 (ru) 2002-12-20 2010-04-30 Пфайзер Продактс Инк. Производные пиримидина для лечения патологического роста клеток
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US20050085479A1 (en) * 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
US7897607B2 (en) * 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06011658A (es) 2004-05-14 2006-12-14 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
TW200724142A (en) * 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
US20090137550A1 (en) * 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
EP1865959A2 (en) * 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
US7910595B2 (en) 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
CN101384592A (zh) * 2005-12-21 2009-03-11 艾博特公司 抗病毒化合物
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2898631C (en) 2013-01-23 2023-06-13 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
DK3143025T3 (da) * 2014-05-15 2019-12-09 Hoffmann La Roche Forbindelser til behandling af spinal muskelatrofi
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
US9573952B2 (en) 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN108135907A (zh) 2015-08-21 2018-06-08 奥尔德拉医疗公司 氘化化合物和其用途
LT3413892T (lt) 2016-02-12 2022-06-10 Cytokinetics, Incorporated Tetrahidroizochinolino dariniai
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
MX2020003425A (es) * 2017-10-10 2020-07-29 Aldeyra Therapeutics Inc Tratamiento de trastornos inflamatorios.
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
JP7505786B2 (ja) 2018-09-25 2024-06-25 アルデイラ セラピューティクス， インコーポレイテッド ドライアイ疾患を処置するための製剤
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
ES2128544T3 (es) * 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Ｉｃカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
JPH10506126A (ja) * 1995-05-12 1998-06-16 ニューロゲン コーポレイション 新規なデアザプリン誘導体；ｃｒｆ１特異性リガンドの新規なクラス
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0778277B1 (en) * 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
WO1997029109A1 (en) 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as crf receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
EP0920429A1 (en) 1999-06-09
IS4948A (is) 1999-01-19
BG103143A (en) 1999-09-30
DE69719193T2 (de) 2003-09-25
BR9710808A (pt) 1999-08-17
CZ292806B6 (cs) 2003-12-17
AR008829A1 (es) 2000-02-23
EA199900083A1 (ru) 1999-08-26
AP9701052A0 (en) 1997-10-31
ZA976954B (en) 1999-02-05
US6492520B1 (en) 2002-12-10
JP2000501116A (ja) 2000-02-02
IL128188A0 (en) 1999-11-30
PA8435201A1 (es) 1999-12-27
DZ2289A1 (fr) 2002-12-25
ES2191183T3 (es) 2003-09-01
NO313293B1 (no) 2002-09-09
UY24655A1 (es) 2000-09-29
CO4900060A1 (es) 2000-03-27
EA003188B1 (ru) 2003-02-27
YU5399A (sh) 2002-03-18
WO1998005661A1 (en) 1998-02-12
DE69719193D1 (de) 2003-03-27
NO990544L (no) 1999-03-31
CN1227552A (zh) 1999-09-01
KR20000029843A (ko) 2000-05-25
TR199900228T2 (xx) 1999-03-22
SK14099A3 (en) 2000-05-16
PE97098A1 (es) 1999-01-12
HRP970432A2 (en) 1998-08-31
CN1093130C (zh) 2002-10-23
CA2262692C (en) 2002-06-11
EP0920429B1 (en) 2003-02-19
AP1096A (en) 2002-08-26
ATE232863T1 (de) 2003-03-15
CA2262692A1 (en) 1998-02-12
GT199700089A (es) 1999-01-26
HK1021734A1 (en) 2000-06-30
CZ41199A3 (cs) 2000-01-12
SA97180334A (ar) 2005-12-03
TW550265B (en) 2003-09-01
NO990544D0 (no) 1999-02-05
NZ333727A (en) 2000-09-29
PL331602A1 (en) 1999-08-02
AU3356397A (en) 1998-02-25
AU709203B2 (en) 1999-08-26
JP3345021B2 (ja) 2002-11-18
HRP970432B1 (en) 2002-10-31
MA24296A1 (fr) 1998-04-01
OA10970A (en) 2001-11-05
ID17980A (id) 1998-02-12
TNSN97135A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
NO990544D0 (no) Substituerte pyrido- eller pyrimido-inneholdende 6,6 eller 6,7-bycykliske derivater
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
PT901474E (pt) Derivados de aril-pirimidina.
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
TR27961A (tr) Sübstitüe edilmis 1,2,3,4 -tetrahidro-5-nitro-pirimidinler.
TR199802520A3 (tr) 1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
DK1015467T3 (da) 6,9-brobundne erythromycinderivater
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
DE69814441D1 (de) 6,11-verbrückte erythromycinderivate
NL1005675A1 (nl) Polytriazinederivaten-bevattende polyalkylpiperidinyloxy- of polyalkylpiperidinylaminogroepen.
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
ES1034273Y (es) Maleta-expositor transformable, perfeccionada.
TR199700927A3 (tr) N-Benzilazolyum türevleri.
SI0920429T1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
ES1033065Y (es) Conjunto canula-tapa, perfeccionado.
ES1034802Y (es) Tope convertible en percha.
ITRC960004A0 (it) Vergafa m.c.